Current and Future Aspects of Smart Nanotheranostic Agents in Cancer Therapeutics
Despite the wide range of knowledge and information about cancer and advances in its treatment, still it is among the leading cause of mortality. Scientists around the globe are working on developing the new strategies to combat this fatal disease, and fortunately significant advances have already been achieved. In this regard, nanomedicines can play a vital role by improving the bio-distribution and the target site delivery of chemotherapeutics. Along with therapeutic applications, nanomedicine formulations have been used for imaging purposes as well. Nanotheranostics is a relatively new but flourishing field, which combines the diagnosis and therapy for personalized treatment. Combining the nanomaterials of diverse origins, e.g., polymers, liposomes, micelles, and antibodies, scientists have successfully developed the smart nanoparticles for both diagnostics and therapeutics at the same time in vivo. In addition, theranostics can be conjugated with bio-ligands for targeted drug delivery to treat and monitor the treatment response at molecular level. Potential applications of nanotheranostic medicines are assessment of drug biodistribution, site-targeted drug delivery, and visualization of drug release at the delivery site. These applications help to optimize the strategies based on triggered drug release and the prediction of therapeutic responses. In the near future, nanotheranostics are the practical solution for cancer and other lethal diseases to cure or at least treat them in the early stage.
This chapter summarizes the smart nanoparticles, developed for the simultaneous imaging and therapy, approaches for their targeted delivery, current applications and the challenges in their development and future perspectives for cancer therapy.
KeywordsCancer Nanotheranostics Chemotherapy Nanoparticles
- Elad S, Zadik Y, Hewson I, Hovan A, Correa MEP, Logan R, Elting LS, Spijkervet FK, Brennan MT. A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support Care Cancer. 2010;18(8):993–1006.PubMedCrossRefPubMedCentralGoogle Scholar
- Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2:17–9.Google Scholar
- Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng G-S. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21(3):389–401.e381.CrossRefGoogle Scholar
- Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29(7):934.PubMedPubMedCentralCrossRefGoogle Scholar
- Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654.PubMedPubMedCentralCrossRefGoogle Scholar
- Wang L-S, Chuang M-C, Ho J-aA. Nanotheranostics—a review of recent publications. Int J Nanomed. 2012;7:4679.Google Scholar
- WHO. Cancer fact sheet N 297. 2015.Google Scholar
- World Health Organization. Cancer fact sheet. Updated Feb 2017.Google Scholar